Quadrant Capital Group’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.04M | Sell |
14,319
-82
| -0.6% | -$44.5K | 0.21% | 63 |
|
|
2025
Q4 | $8.34M | Buy |
14,401
+124
| +0.9% | +$70.1K | 0.25% | 49 |
|
|
2025
Q3 | $6.92M | Buy |
14,277
+3,369
| +31% | +$1.57M | 0.23% | 55 |
|
|
2025
Q2 | $4.42M | Buy |
10,908
+2,126
| +24% | +$889K | 0.16% | 91 |
|
|
2025
Q1 | $4.37M | Buy |
8,782
+3,460
| +65% | +$1.87M | 0.16% | 73 |
|
|
2024
Q4 | $2.77M | Buy |
5,322
+224
| +4% | +$123K | 0.19% | 61 |
|
|
2024
Q3 | $3.15M | Buy |
5,098
+142
| +3% | +$84.1K | 0.22% | 57 |
|
|
2024
Q2 | $2.74M | Buy |
4,956
+141
| +3% | +$80.8K | 0.2% | 63 |
|
|
2024
Q1 | $2.8M | Buy |
4,815
+33
| +0.7% | +$18.5K | 0.22% | 61 |
|
|
2023
Q4 | $2.54M | Sell |
4,782
-100
| -2% | -$48.4K | 0.22% | 62 |
|
|
2023
Q3 | $2.47M | Buy |
4,882
+281
| +6% | +$150K | 0.25% | 56 |
|
|
2023
Q2 | $2.4M | Sell |
4,601
-176
| -4% | -$95K | 0.24% | 59 |
|
|
2023
Q1 | $2.75M | Sell |
4,777
-155
| -3% | -$87.4K | 0.29% | 51 |
|
|
2022
Q4 | $2.72M | Buy |
4,932
+136
| +3% | +$72.1K | 0.31% | 48 |
|
|
2022
Q3 | $2.43M | Buy |
4,796
+290
| +6% | +$162K | 0.32% | 43 |
|
|
2022
Q2 | $2.45M | Buy |
4,506
+9
| +0.2% | +$4.95K | 0.33% | 49 |
|
|
2022
Q1 | $2.66M | Buy |
4,497
+21
| +0.5% | +$12.1K | 0.32% | 51 |
|
|
2021
Q4 | $2.99M | Buy |
4,476
+27
| +0.6% | +$16.9K | 0.36% | 46 |
|
|
2021
Q3 | $2.54M | Buy |
4,449
+167
| +4% | +$91.7K | 0.35% | 45 |
|
|
2021
Q2 | $2.16M | Buy |
4,282
+115
| +3% | +$54.3K | 0.31% | 48 |
|
|
2021
Q1 | $1.9M | Buy |
4,167
+240
| +6% | +$115K | 0.31% | 47 |
|
|
2020
Q4 | $1.83M | Buy |
3,927
+45
| +1% | +$21.1K | 0.34% | 46 |
|
|
2020
Q3 | $1.71M | Buy |
3,882
+129
| +3% | +$53.3K | 0.37% | 44 |
|
|
2020
Q2 | $1.36M | Sell |
3,753
-2,622
| -41% | -$879K | 0.3% | 60 |
|
|
2020
Q1 | $1.81M | Buy |
6,375
+307
| +5% | +$96.8K | 0.3% | 60 |
|
|
2019
Q4 | $1.93M | Buy |
6,068
+1,078
| +22% | +$327K | 0.23% | 69 |
|
|
2019
Q3 | $1.44M | Sell |
4,990
-49
| -1% | -$14K | 0.22% | 73 |
|
|
2019
Q2 | $1.46M | Sell |
5,039
-130
| -3% | -$35.8K | 0.23% | 75 |
|
|
2019
Q1 | $1.4M | Buy |
5,169
+2,016
| +64% | +$502K | 0.25% | 70 |
|
|
2018
Q4 | $692K | Sell |
3,153
-17
| -0.5% | -$3.99K | 0.18% | 91 |
|
|
2018
Q3 | $761K | Buy |
3,170
+27
| +0.9% | +$6.21K | 0.22% | 79 |
|
|
2018
Q2 | $639K | Hold |
3,143
| – | – | 0.22% | 87 |
|
|
2018
Q1 | $638K | Buy |
3,143
+33
| +1% | +$6.93K | 0.23% | 83 |
|
|
2017
Q4 | $581K | Buy |
3,110
+33
| +1% | +$6.32K | 0.23% | 88 |
|
|
2017
Q3 | $573K | Buy |
3,077
+19
| +0.6% | +$3.44K | 0.24% | 84 |
|
|
2017
Q2 | $510K | Buy |
3,058
+145
| +5% | +$24.4K | 0.23% | 88 |
|
|
2017
Q1 | $439K | Buy |
2,913
+104
| +4% | +$15.9K | 0.19% | 103 |
|
|
2016
Q4 | $387K | Sell |
2,809
-35
| -1% | -$5.16K | 0.19% | 89 |
|
|
2016
Q3 | $442K | Buy |
2,844
+18
| +0.6% | +$2.77K | 0.29% | 64 |
|
|
2016
Q2 | $410K | Buy |
2,826
+43
| +2% | +$6.35K | 0.28% | 67 |
|
|
2016
Q1 | $387K | Buy |
2,783
+94
| +3% | +$12.6K | 0.25% | 69 |
|
|
2015
Q4 | $373K | Buy |
2,689
+92
| +4% | +$12.3K | 0.26% | 82 |
|
|
2015
Q3 | $313K | Hold |
2,597
| – | – | 0.22% | 88 |
|
|
2015
Q2 | $333K | Buy |
+2,597
| New | +$339K | 0.21% | 88 |
|
Other funds holding TMO
VCM
Quadrant Capital Group's TMO Position: Q1 2026 in Review
Quadrant Capital Group reduced its Thermo Fisher Scientific (TMO) stake by 0.57% in Q1 2026, selling an estimated $44.5K and leaving 14,319 shares worth $7.04M. The position accounts for 0.21% of the portfolio, ranked #63.
Quadrant Capital Group first reported a position in TMO in Q2 2015 and has held it in 44 quarters since. The position peaked at $8.34M in Q4 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Quadrant Capital Group held 14,319 shares of Thermo Fisher Scientific worth $7.04M as of Q1 2026.
- Quadrant Capital Group sold 82 Thermo Fisher Scientific shares in Q1 2026, an estimated $44.5K.
- Thermo Fisher Scientific made up 0.21% of Quadrant Capital Group's portfolio in Q1 2026, its #63 holding.
- Quadrant Capital Group first reported a position in Thermo Fisher Scientific in Q2 2015 and has held it in 44 quarters since.
- Quadrant Capital Group's Thermo Fisher Scientific position peaked at $8.34M in Q4 2025.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.